SPDR S&P Biotech ETF (XBI)

NYSEARCA: XBI · IEX Real-Time Price · USD
87.27
-1.60 (-1.80%)
Aug 19, 2022 4:00 PM EDT - Market closed
-1.80%
Assets $8.37B
NAV $89.54
Expense Ratio 0.35%
PE Ratio 10.18
Shares Out 93.45M
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date Mar 22, 2021
1-Year Return -26.75%
Volume 7,732,261
Open 87.69
Previous Close 88.87
Day's Range 86.74 - 88.60
52-Week Low 61.78
52-Week High 136.61
Beta 1.08
Holdings 135
Inception Date Jan 31, 2006

About XBI

In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (S&P TMI).

Asset Class Equity
Sector Biotech
Region North America
Issuer State Street Global Advisors
Stock Exchange NYSEARCA
Ticker Symbol XBI
Index Tracked S&P Biotechnology Select Industry Index

Top 10 Holdings

16.71% of assets
Name Symbol Weight
Global Blood Therapeutics GBT 2.57%
Karuna Therapeutics KRTX 2.24%
ChemoCentryx CCXI 1.76%
Twist Bioscience TWST 1.57%
Beam Therapeutics BEAM 1.57%
Alnylam Pharmaceuticals ALNY 1.47%
Apellis Pharmaceuticals APLS 1.45%
PTC Therapeutics PTCT 1.38%
Sarepta Therapeutics SRPT 1.37%
Natera NTRA 1.34%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Mar 22, 2021 $0.040 Mar 25, 2021
Dec 21, 2020 $0.176 Dec 24, 2020
Sep 21, 2020 $0.08897 Sep 24, 2020
Jun 22, 2020 $0.01676 Jun 25, 2020
Dec 20, 2019 $0.00086 Dec 26, 2019
Sep 20, 2019 $0.00319 Sep 25, 2019
Full Dividend History

News

Biotech ETFs Are on the Mend

Biotechnology sector-related exchange traded funds are making a swift rebound as a spate of dealing making and new drug approvals helped reinvigorate the segment. For instance, the SPDR S&P Biotech ETF ...

Other symbols: IBB

Biotech Rebounds on Optimism and Deal Making

The sector had tumbled in the market selloff, but it is getting a boost from big investors and big pharmaceutical companies.

How Are Biotech ETFs Reacting to Q2 Earnings Releases?

he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.

Other symbols: AMGNBBHBIIBGILDIBB

Hedge fund says there are 2 areas in the U.S. in which it has 'aggressive positions'

Thomas Hayes of Great Hill Capital explains why it's positive on U.S. biotech and auto suppliers.

Other symbols: SMH

Biotech ETFs Slip After Novavax Cuts 2022 Guidance

Biotechnology sector-related exchange traded funds retreated with Novavax Inc. (NasdaqGS: NVAX), plunging after the vaccine developer cut its 2022 revenue guidance in half. On Tuesday, the iShares Genom...

Other symbols: GERMIDNASBIO

Biotech Wins Last Week: 5 Best ETFs

The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.

Other symbols: BBCBBPPFESBIO

Biotech ETFs Rally as Global Blood Therapeutics Surges on Potential Pfizer Deal

Biotechnology sector-related exchange traded funds continued to rally Friday on reports that Pfizer Inc. (NYSE: PFE) is looking to acquire Global Blood Therapeutics (NasdaqGS: GBT). On Friday, the Virtu...

Other symbols: BBPSBIO

Biotech ETFs Advance on Speculation of a Takeover Bid for Global Blood Therapeutics

Global Blood Therapeutics (NasdaqGS: GBT) shares climbed Thursday, lifting biotechnology sector-related exchange traded funds, on speculation of takeover bids for the small drug developer. On Thursday, ...

Other symbols: BBPSBIO

The Bull Market in Biotech Is Still Going Strong

The SPDR S&P Biotech ETF is up 32.5% since the close of trading on June 14, nearly triple the gain in the S&P 500.

The 3 Best Market Sectors for the Second Half of 2022

Inflation fears delivered the worst first-half performance for the stock market since 1970. Fortunately, the second half is unlikely to echo the destruction because equities have already baked in a mild...

Other symbols: XLEXLK

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Is It Time to Buy the Dip With Biotech Stocks?

Right now, it's even riskier to buy biotechs than normal.

Has the Market Bottomed? 6 ETFs in High Momentum

These ETFs are in high momentum as some traders believe that markets have reached a bottom.

Other symbols: DATFUTYITBKBWDRTH

ETF Filings Heat Up In July

A range of compelling new offerings from stalwarts and newcomers are shaking up the industry.

Other symbols: ARKKGDXKWEBTLTFLOT

Final Trades: XBI, UNH, KWEB & DHR

The final trades of the week. With CNBC's Joe Kernen and the Fast Money traders, Tim Seymour, Jeff Mills, Bonawyn Eison and Steve Grasso.

Other symbols: DHRKWEBUNH

Final Trades: CVS, Disney, Biotech & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: CVSDISAMD

Biotech Public Offerings at 10-Year Low

No matter how you slice it, this has been a poor year for biotechnology stocks. Not only is the SPDR S&P Biotech ETF ( XBI , Financial) down nearly 29% year to date, but biotech initial public offerings...

Other symbols: BLTEHLVXPEPGTAK

5 ETFs Riding High on the Biotech Comeback

Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.

Other symbols: BBCBBPCNCRSBIO

Health-care stocks could do well during economic contraction, says Renaissance's Jeff Degraaf

Jeff Degraaf, Renaissance Macro Research chairman, joins 'Closing Bell: Overtime' to discuss biotech and other sectors to watch.

Other symbols: IBBXLB

Biotech ETFs Are Making a Comeback

Biotechnology stocks and sector-related exchange traded funds have been gaining momentum as investors return to this downtrodden segment of the market. Over the past month, the Virtus LifeSci Biotech Cl...

Other symbols: BBCBBPSBIO

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Use This 1 Genius Trick for Finding Dirt Cheap Biotech Stocks in the Bear Market

This metric will show you which companies are being valued at potentially unreasonably low levels.

Biotech stocks will ‘outperform' in the balance of 2022: Fahmy

A new bull market is unlikely until the U.S. Federal Reserve starts to go easy on the interest rates. Still, there are opportunities that could be rewarding in the back half of 2022.

Biotech Stocks Finally Rose in June. What Does It Mean?

Not all analysts agree that the sector's gains in June mean its rout is over.

Other symbols: IBB

Joseph Fahmy: Biotech is likely to outperform in the second half of the year

Joseph Fahmy, Managing Director at Zor Capital, joins Worldwide Exchange to discuss why he's bullish on biotech stocks, including the XBI ETF.